No Clinically Significant Interaction Between Restavit and Apixaban
There is no documented clinically significant interaction between Restavit (diphenhydramine) and apixaban, and no dose adjustment of apixaban is required when these medications are used together.
Mechanism Analysis
Diphenhydramine does not interact with apixaban through the relevant metabolic pathways:
Apixaban metabolism: Apixaban is primarily metabolized by CYP3A4 (with minor contributions from CYP1A2, 2C8, 2C9, 2C19, and 2J2) and is a substrate of P-glycoprotein (P-gp) 1
Diphenhydramine's enzymatic activity: Diphenhydramine is known to inhibit CYP2D6, not CYP3A4 or P-gp 2, 3. Studies demonstrate diphenhydramine significantly inhibits CYP2D6-mediated metabolism of drugs like venlafaxine and metoprolol, but this enzyme is not involved in apixaban metabolism
No overlap: Since diphenhydramine does not inhibit or induce CYP3A4 or P-gp (the pathways critical for apixaban), no pharmacokinetic interaction is expected
FDA Labeling Guidance
The FDA label for apixaban specifically identifies drugs requiring dose adjustment or avoidance 1:
- Dose reduction required: Combined P-gp and strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir)
- Avoid: Combined P-gp and strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort)
- Diphenhydramine is not listed in either category
Bleeding Risk Considerations
While there is no pharmacokinetic interaction, consider the following:
Sedation and fall risk: Diphenhydramine causes significant sedation, particularly in older adults, which could increase fall risk and subsequent bleeding complications in anticoagulated patients 4
No pharmacodynamic bleeding interaction: Unlike NSAIDs or antiplatelet agents, diphenhydramine does not directly affect hemostasis or platelet function 1
Clinical Recommendations
Use both medications together without apixaban dose adjustment, but:
- Monitor for increased sedation and fall risk, especially in elderly patients
- Consider second-generation antihistamines (cetirizine, loratadine) as safer alternatives to diphenhydramine in anticoagulated patients to minimize fall risk 4
- Maintain standard apixaban dosing based on established criteria (renal function, age, weight) 1
Important Caveat
The comprehensive analysis of drug interactions with apixaban from VigiBase revealed that 67% of reported drug-drug interactions were "not described or understood," with most clinically significant interactions being pharmacodynamic (affecting bleeding risk) rather than pharmacokinetic 5. However, diphenhydramine was not identified as a problematic agent in this large safety database.